He has conquered Covid for the time being, and now the CEO of BioNTech says he wants to turn his attention back to his first interest: cancer. He has conquered Covid for the time being, and now the ...

SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

BioNTech CEO Ugur Sahin, whose company is Pfizer's vaccine partner in Europe, told reporters on Tuesday that the "likelihood" their shot would work with regards to the UK variant was "relatively high, ...

BioNTech struck a partnership with DualityBio Monday morning to delve into next-generation antibody-drug conjugate (ADC) therapeutics in cancer and autoimmune diseases. The deal gives BioNTech access ...

JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (BNTX) (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech (NTGN), visited Israel to meet with ...

BioNTech is acquiring InstaDeep for £362 million, or about $440 million in initial cash, as part of its efforts to bolster its cancer immunotherapy and vaccine pipelines beyond COVID-19, the company ...

Currently, BA.5 is the dominant viral strain of COVID-19 in the U.S. American pharmaceutical company Pfizer and its German partner BioNTech announced Friday that a booster dose of their bivalent COVID ...

BERLIN, Oct 30 (Reuters) - BioNTech (22UAy.F), opens new tab, Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly ...

New York City-based drugmaker Pfizer and BioNTech, the German biotech company it partnered with to develop a COVID-19 vaccine, estimate their vaccine could win regulatory approval as early as this ...

American pharmaceutical company Pfizer and its German partner BioNTech announced Friday that a booster dose of their bivalent COVID-19 vaccine performs better against two circulating versions of the ...